Literature DB >> 6289736

Aminoglycoside-resistant gram-negative bacilli in a community hospital: comparative in vitro activity of cefotaxime, moxalactam, cefoperazone, and piperacillin.

C R Magnussen, M T Sammartino, K D Ernest.   

Abstract

All aminoglycoside-resistant gram-negative bacilli isolated during 1 year at a community hospital were tested for in vitro sensitivity to cefotaxime, moxalactam, cefoperazone, and piperacillin. The majority of Enterobacteriaceae were susceptible to all four antibiotics. Cefoperazone and piperacillin were the most active for pseudomonas aeruginosa, and activity for other nonfermentative gram-negative bacilli was variable.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6289736      PMCID: PMC183692          DOI: 10.1128/AAC.22.1.154

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  In-vitro activity of cefotaxime against gentamicin and mezlocillin resistant strains.

Authors:  I Braveny; H Dickert
Journal:  Lancet       Date:  1979-11-10       Impact factor: 79.321

2.  Gentamicin/amikacin-resistant gram-negative bacilli at Detroit General Hospital, 1975-1976.

Authors:  L Jauregui; R D Cushing; A M Lerner
Journal:  Am J Med       Date:  1977-06       Impact factor: 4.965

3.  Resistance to gentamicin, tobramycin and amikacin among clinical isolates of bacteria.

Authors:  R C Moellering; C Wennersten; L J Kunz; J W Poitras
Journal:  Am J Med       Date:  1977-06       Impact factor: 4.965

4.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

5.  Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli.

Authors:  T O Kurtz; D J Winston; J A Hindler; L S Young; W L Hewitt; W J Martin
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

6.  Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli.

Authors:  W H Hall; B J Opfer; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

7.  In vitro studies of piperacilin, a new semisynthetic penicillin.

Authors:  D J Winston; D Wang; L S Young; W J Martin; W L Hewitt
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

8.  Antibacterial activity of HR-756, cefoxitin and cefuroxine against multiply antibiotic-resistant strains of Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  N J Legakis; D A Kafetzis; C J Papadatos; J T Papavassiliou
Journal:  Chemotherapy       Date:  1980       Impact factor: 2.544

9.  The sensitivity of gentamicin-resistant gram-negative bacilli to cefotaxime, other cephalosporins and aminoglycosides.

Authors:  M Stephens; M Potten; A J Bint
Journal:  Infection       Date:  1979       Impact factor: 3.553

10.  In vitro activity of LY127935.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1979-10       Impact factor: 5.191

View more
  2 in total

1.  Aztreonam in the treatment of severe urinary tract infections in pediatric patients.

Authors:  F Rusconi; B M Assael; A Boccazzi; R Colombo; R M Crossignani; L Garlaschi; L Rancilio
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

2.  False-susceptible results from the MS-2 system used for testing resistant Pseudomonas aeruginosa against two third-generation cephalosporins, moxalactam and cefotaxime.

Authors:  L L Stone; D L Jungkind
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.